S&P7,659.4−1.11%16 Oct
Nasdaq29,187.6−2.53%16 OctStoxx6,204.2+0.58%16 OctFTSE10,796.3−0.79%Nikkei64,916.7−0.62%Hang Seng24,186.8+0.52%16 Oct10Y5.10%+1 bp16 OctS&P7,659.4−1.11%16 OctNasdaq29,187.6−2.53%16 OctStoxx6,204.2+0.58%16 OctFTSE10,796.3−0.79%Nikkei64,916.7−0.62%Hang Seng24,186.8+0.52%16 Oct10Y5.10%+1 bp16 OctS&P7,659.4−1.11%16 Oct
Markets

Foundayo is a named line

A Lilly quarter discloses Foundayo as a named revenue line, or a prescription run-rate in a filing, by 31 Dec 2026.

Resolves by
31 Dec 2026
Confirm
The pill was a product.
Kill
An approval, not a cluster.
Grade

Open.

Related writing

No article rides on this one yet.

← The Claims